logo
Earth's Crust Is Hiding Vast Reserves of Hydrogen – Here's How We Can Find It

Earth's Crust Is Hiding Vast Reserves of Hydrogen – Here's How We Can Find It

Yahoo23-05-2025
We already rely heavily on hydrogen gas as a fuel source, and it's considered key to reaching crucial carbon-neutral goals.
Now researchers have come up with a recipe for naturally forming hydrogen, which could help locate the vast reserves of the gas that are locked away in Earth's crust.
Tapping into these reserves, the researchers say, could meet our hydrogen energy needs for up to 170,000 years. It would mean we no longer have to use hydrocarbons to produce hydrogen – which contributes to carbon dioxide emissions.
The new recipe was put together by a team from the UK and Canada. The cooking time, they estimate, is around a billion years.
"We have successfully developed an exploration strategy for helium and a similar first principles approach can be taken for hydrogen," says geoscientist Jon Gluyas, from Durham University in the UK.
Hydrogen forms in Earth's crust as water interacts with rocks that are either rich in iron or contain radioactive elements. Certain other criteria must be met too, in terms of temperature, pressure, timing, and containment.
By considering all these factors and mapping where they are present on Earth, the researchers came to the conclusion that there could be plenty of hydrogen waiting to be tapped into – as there is at the Bourakebougou site in Mali, for example.
The next problem is finding it. The recipe put together in this study lists the ingredients that experts can look for – and they all need to be included for hydrogen to be found. The research also acts like a treasure map of sorts, pointing to regions where conditions are favorable for hydrogen formation.
"We know for example that underground microbes readily feast on hydrogen," says earth scientist Barbara Sherwood Lollar, from the University of Toronto.
"Avoiding environments that bring them into contact with the hydrogen is important in preserving hydrogen in economic accumulations."
Many other researchers are also busy with this task. A study published earlier this year suggested there could be extensive hydrogen reserves locked away in the world's mountain ranges, created by the push and pull of tectonic plates.
Hydrogen is crucial today, particularly in fertilizer production to help feed the world. Demand for the gas is expected to surge, from 90 million metric tons (99 million US tons) in 2022 to 540 million metric tons by 2050. While there are artificial ways of creating hydrogen, they're expensive and not carbon neutral.
There's still a lot of work to do to locate and extract natural hydrogen – and it's going to be a finite resource when we do find it – but research like this suggests it's a viable option for a future with cleaner energy.
"One successful exploration recipe that is repeatable will unlock a commercially competitive, low-carbon hydrogen source that would significantly contribute to the energy transition," says geochemist Chris Ballentine, from the University of Oxford.
The research has been published in Nature Reviews Earth & Environment.
Piles of Penguin Poop Could Surprisingly Help Cool Antarctica
'Forever Chemicals' Found in Popular US Beers, Above EPA Limits
NOAA Forecasts a Busy Hurricane Season For 2025. What's Fueling It?
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

This 2016 Chloë Grace Moretz Sci-Fi Flop Is A Streaming Hit On Netflix
This 2016 Chloë Grace Moretz Sci-Fi Flop Is A Streaming Hit On Netflix

Yahoo

time3 hours ago

  • Yahoo

This 2016 Chloë Grace Moretz Sci-Fi Flop Is A Streaming Hit On Netflix

We may receive a commission on purchases made from links. Netflix's Top 10 charts have a knack for pulling off surprises — and sometimes those surprises aren't necessarily winners. Case in point: "The 5th Wave," a 2016 sci-fi movie starring Chloë Grace Moretz that just popped into the streamer's Top 10 in the U.S. (as of this writing, it's currently sitting at #9). Based on the YA novel by Rick Yancey, the story features an alien invasion, humanity on the brink, and a teenager trying to survive. The thing is, this movie wasn't exactly a beloved hit in its day. Critics ripped it to shreds, audiences weren't much kinder, and it pretty much disappeared without a trace as soon as it left theaters. Yet here it is, almost a decade later, getting a fresh wave of attention. That's because Netflix, as we've seen time and time again, can turn long-forgotten titles into overnight streaming "hits," thanks to a mix of star power, curiosity, and the platform's high-profile Top 10 rankings — which, as I've pointed out across too many posts to count (like this one), essentially reward recency as much as actual quality. Read more: 14 Apple TV+ Shows That Are As Good As Or Better Than Anything On Netflix Netflix Resurrects Another Box Office Bomb For some perspective, "The 5th Wave" came out back in 2016, the same year that gave us blockbusters like "Rogue One" and "Deadpool." Meaning, it's understandable if a movie like "The 5th Wave" slipped under your radar the first time around. On Rotten Tomatoes, the movie is currently sitting at a pretty brutal 17% critics score, with audiences rating it 38% based on more than 25,000 reviews, and that rare alignment between critics and viewers tells you just about everything you need to know. Not that it matters to Netflix's almighty algorithm. The streamer's Top 10 lists thrive on the here-and-now. A title gets added into the mix, viewers maybe spot a familiar actor's face in the thumbnail, and curiosity does the rest. Sometimes, that rediscovery turns into genuine enthusiasm. One thing that a title's re-entry into the Netflix Top 10 doesn't tell you is just how many people tried it out and ended up frustrated with their decision. In this case, it's probably a mix of both. Moretz still has name recognition, the alien invasion hook is an easy sell, and the movie hasn't been front-and-center in years. Whether viewers make it to the closing credits without regret is another story. But if nothing else, "The 5th Wave" proves Netflix will dust off just about anything — the good, the bad, and everything in between. Read the original article on BGR.

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

Yahoo

time4 hours ago

  • Yahoo

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S. CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ('BioVie' or the 'Company'), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that a poster highlighting the design and enrichment strategy of its ongoing Phase 2 ADDRESS-LC trial will be presented at the Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes, held August 10–13 in Santa Fe, New Mexico. Long COVID is now recognized as a leading neurological condition that has affected an estimated 400 million individuals worldwide,1,2 .The Centers for Disease Control has reported that 6.9% of adults in the United States (more than 18 million individuals) currently or previously had long COVID.3 The neurological symptoms such as persistent cognitive dysfunction and fatigue can last for years and currently there are no FDA-approved treatment options.2,4 ADDRESS-LC (NCT06847191; is currently-enrolling participants for a phase 2, multicenter, double-blind, randomized, placebo-controlled, 16-week study evaluating the efficacy, safety, and tolerability of bezisterim in adult participants with Long COVID who are enriched for cognitive impairment and fatigue. The Phase 2 study is fully funded by a grant from the U.S. Department of Defense (DOD). Bezisterim is an anti-inflammatory agent being developed for Long COVID and other neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD), in which TLR-driven inflammation contributes to cognitive decline. It has been shown to inhibit both TLR4-induced signaling and inflammatory NF-κB signaling,4 and is orally available, not immunosuppressive, and crosses the blood-brain barrier.5,6 In clinical trials of AD and PD, bezisterim has demonstrated a favorable safety and tolerability profile. "The ADDRESS-LC trial was designed with input from Long COVID patients with the goal of helping to address the tremendous unmet needs of this community," said Penelope Markham, PhD, Senior Vice President of BioVie's Liver Disease and Long COVID Programs, who will be presenting the design. "Ongoing neuroinflammation has been observed in many patients with Long COVID, and BioVie leveraged its experience in studying other neurodegenerative diseases characterized by inflammation to create a unique trial that will both rigorously evaluate bezisterim in patients and add to our understanding of Long COVID pathology as a whole'. The ADDRESS-LC trial features a novel design informed by direct input from clinicians and patients, incorporating pragmatic elements to enhance relevance and feasibility. The study employs an enrichment strategy to increase the likelihood of signal detection and stratifies participants by symptom duration (<2 years or ≥2 years) to account for potential development of refractory symptoms, as well as by age (18–45 or 46–64) to address age-related differences in cognition. Key endpoints include the change in performance on a bespoke Cogstate Cognitive Battery, an objective tool designed to assess bezisterim's potential to improve neurocognitive symptoms such as cognitive impairment associated with Long COVID. Details for the oral and poster presentations are as follows: Oral Presentation and Poster Details: Title: A Phase 2 Trial Designed to Enhance Signal Detection in an Evaluation of Bezisterim (NE3107) For the Treatment of Neurological Symptoms of Long COVID Symposia Spotlight: 2:15pm-4:30pm (MT), Monday, August 11 Poster displayed from 7:30pm-10:00pm (MT), Tuesday August 12 Poster number: 2011 To learn more about ADDRESS-LC trial enrollment, visit About Bezisterim Bezisterim (NE3107) is an orally bioavailable, blood-brain barrier (BBB)-permeable modulator of inflammation and insulin-sensitizer. In addition, it is not immunosuppressive and has a low risk of drug-drug interaction. By binding to ERK and selectively modulating NFκB activation and TNF-α production, BioVie believes that bezisterim may offer clinical improvements in several disease indications, including Alzheimer's disease, Parkinson's disease and long COVID. In Parkinson's disease, BioVie is currently enrolling patients in the Phase 2 SUNRISE-PD clinical trial evaluating the safety and efficacy of bezisterim on motor and non-motor symptoms in patients who have not been treated with carbidopa/levodopa, with topline data expected in late 2025 or early 2026. A previous Phase 2 study of bezisterim in Parkinson's disease (NCT05083260) completed in 2022, and data presented at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Gothenburg, Sweden in March 2023 showed significant improvements in 'morning on' symptoms and clinically meaningful improvement in motor control in patients treated with a combination of bezisterim and levodopa versus patients treated with levodopa alone, and no drug-related adverse events. In long COVID, bezisterim has the potential to reduce neurological symptoms including fatigue and cognitive dysfunction. Persistently circulating viral spike proteins are believed to trigger TLR-4 driven activation of NFκB and the subsequent expression of inflammatory cytokines (IL-6, TNF, IFNg). BioVIe's Phase 2 ADDRESS-LC study, is a randomized (1:1), placebo-controlled, multicenter trial in approximately 200 patients to evaluate the safety, tolerability and potential efficacy of 3 months of treatment with bezisterim to reduce the neurocognitive symptoms associated with long COVID, including difficulty concentrating or remembering things ('brain fog') and fatigue. In Alzheimer's disease, BioVie conducted and reported efficacy data on its Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate bezisterim in patients who have mild-to-moderate Alzheimer's disease (NCT04669028) in 2023. Results of a Phase 2 investigator-initiated trial (NCT05227820) showing bezisterim-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trials on Alzheimer's Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer's disease. Terms of the Department of Defense Award The work is supported by the Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, by a fully funded award in the amount of $13.13 million through the Peer-Reviewed Medical Research Program (PRMRP) under Award No. HT9425-24-1-0113. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Assistant Secretary of Defense for Health Affairs or the Department of Defense. About BioVie Inc. BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson's disease and long COVID) and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-κB, and the associated neuroinflammation and insulin resistance but not ERK and NFκB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit Forward-Looking Statements This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. REFERENCES Avitzur O. President's Column, 2022. American Academy of Neurology. Accessed June 16, 2025. Al-Aly Z, et al. Nat Med 2024;30:2148-2164. doi:10.1038/s41591-024-03173-6 Ford ND, Agedew A, Dalton AF, Singleton J, Perrine CG, Saydah S. Notes from the Field: Long COVID Prevalence Among Adults — United States, 2022. MMWR Morb Mortal Wkly Rep 2024;73:135–136. DOI: Davis HE, et al. EClinicalMedicine. 2021;38:101019. doi:10.1016/ Reading CL, et al. Neurodegener Dis Manag. 2021;11(4):289-298. doi:10.2217/nmt-2021-0022 Ahlem CN, et al. Int J Clin Exp Med. 2011;4(2):119-135. For Media Inquiries: Contact:Chuck PadalaManaging DirectorLifeSci Advisors, LLCchuck@ Contact:Melyssa WeibleManaging Partner, Elixir Health Public Relations Ph: +1 201-723-5705mweible@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store